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a b s t r a c t
Background: Pakistan introduced Ten-valent pneumococcal-conjugate-vaccine PCV10 in 2012 as a 3 + 0
schedule without catch-up.
Methods: Children <2 years old in Matiari, Sindh provided nasopharyngeal swabs between 2014 and
2018, which were cultured for pneumococcus and serotyped through multiplex PCR at the Aga Khan
University Hospital. Carriage rates over time for Vaccine-Type (VT) and Non-VT (NVT) serotypes were
used to estimate direct, indirect, total and overall effects of vaccination. Regression analysis was used
to determine factors associated with VT carriage.
Results: Pneumococcus was detected in 2370/3140 (75%). VT carriage decreased overall, 16.1–9.6% (p-
trend <0.001); vaccinated (all 3 doses of PCV10 received) 11.3–8.1% (p-trend 0.031) and unvaccinated
(no PCV10 dose received) 17.4–10.3% (p-trend 0.003) with a decline in serotypes 6B, 9V/9A and 19F.
Immunization increased from 41.0% to 68.4% (p-trend 0.001). Direct effect of vaccine was 32.8% (95%
CI 14.7–47.0%) and indirect effect 44.6%(95% CI 40.6–48.6%). Factors associated with decreased VT colo-
nization were education 1–5 years (aOR 0.7, 95%CI 0.6–1.0), history of difficulty breathing (aOR 0.7, 95%CI
0.5–1.0), exposure to smoke (aOR 0.8, 95% CI 0.6–1.0), child fully immunized (aOR 0.7, 95%CI 0.5–1.0) and
enrolled in 3rd (aOR 0.6, 95%CI 0.4–0.8) and 4th (aOR 0.6, 95%CI 0.5–0.9) year of the study whereas his-
tory of runny nose (aOR 1.5, 95% CI 1.2–1.9) was positively associated.
Conclusions: Decrease in VT pneumococcal carriage in vaccinated and unvaccinated children indicates
herd immunity. Sustained increase in vaccine coverage and close long-term surveillance is warranted.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Pneumonia, caused by a number of infectious agents, is the
leading cause of morbidity and mortality in children worldwide.
Streptococcus pneumoniae (pneumococcus) is the leading bacterial
cause contributing to more deaths than all other etiologies com-
bined [1]. There were an estimated 138 million (86–226 million)
episodes of clinical pneumonia and 0.9 million (0.8–1.1 million)
deaths in children less than five years of age in the year 2015 glob-
ally [2]. Although the incidence and mortality from pneumonia has
fallen globally during the Millennium Development Goal (MDG)
era (2000–2015), in Pakistan the incidence has increased by 50%.
There were around 7.1 million (4.2–12.0 million) episodes of clin-
ical pneumonia and around 63,960 pneumonia deaths in children
under the age of five years in Pakistan in the year 2015 [2]. Deaths
due to pneumococcal infections were 318,000 (207,000–395,000)
in this age group with 14,000 (9700–17,000) of these occurring
in Pakistan [3].
https://doi.org/10.1016/j.vaccine.2020.12.066
0264-410X/ 2021 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Pneumococcus has more than 90 known serotypes and resides
asymptomatically in the upper respiratory tract of humans
[1,4,5]. Colonization may be present as early as first few months
of life [6]. In some cases, colonization progresses to invasive or
non-invasive disease with most caused by a limited number of ser-
otypes [7]. The most common of these serotypes responsible for
causing invasive disease are included in pneumococcal conjugate
vaccines like PCV10 and PCV13 [7]. As of June 2020, 146 countries,
including 60 with support from Gavi, the Vaccine Alliance, have
introduced pneumococcal conjugate vaccine in their countries’
immunization program [8]. Various post introduction impact eval-
uation studies have subsequently shown significant decline in
invasive disease as well as carriage. Benefit in many cases have
spilled over to adult population as well as older children and chil-
dren too young to be vaccinated [9–11]. In 2012, Pakistan became
the first country in South Asia to introduce ten valent pneumococ-
cal vaccine (PCV10) in its Expanded Program on Immunization
(EPI) with WHO recommended schedule of three doses given at
6, 10 and 14 weeks of life (3 + 0 schedule). No catch-up immuniza-
tion was offered [12,13].
In this paper, we aim to describe impact of PCV10 on pneumo-
coccal carriage in vaccinated (direct protection) and unvaccinated
children (indirect or herd protection) aged less than two years in
a rural population in Matiari, Sindh, Pakistan. We use point esti-
mate of 26.7% as the baseline Vaccine Type (VT) carriage from a
pre-introduction carriage survey in the same population [14]. We
also describe the socio-demographic and clinical characteristics
associated with VT carriage.
2. Methods
2.1. Study design and participants
This study was carried out from October 2014 to September
2018 in two Union Councils (Khyber and Shah Alam Shah Jee Wasi)
of Matiari in Sindh, Pakistan, having a total population of around
88,739. Matiari is a rural district located 180 km from the Aga Khan
University in Karachi. Average household size is 7, literacy rates are
low with most of the population engaged in agriculture. The site
was chosen because we had previously done a pre-PCV10 intro-
duction carriage survey in the same population in 2012–13, which
provided an estimate of vaccine type pneumococcal carriage in a
vaccine naïve population. PCV10 was introduced in this population
in early part of 2013 as per the EPI schedule with no catchup
immunization.
A background demographic surveillance system (DSS) in the
area provided a frame-work for randomly selecting 15 age eligible
children every week from the available line listing. Each child was
only enrolled once in the study. There were no significant supply
chain issues related to PCV10 encountered during the course of
the study. Vaccination history of the child was collected as a com-
bination of caregiver reported or/and card verified (where avail-
able). PCV10 and pentavalent vaccine follow the same schedule
in Pakistan’s EPI and it is a common practice for the vaccinators
to give PCV10 in the left and pentavalent in right thigh. In instances
where children received only one of the two recommended shots,
the caregivers were enquired about the site of the injection.
Children with nose and throat abnormalities or with a serious
illness requiring hospitalization were excluded from the study.
Data on household demographics, recent clinical history including
hospitalization and outpatient visits, exposure to household smoke
and indoor air pollution was collected by study personnel on
smartphones. A brief clinical exam including measurement of
fever, respiratory rate and observation for chest wall indrawing
was also done.
2.2. Nasopharyngeal swab collection
Nasopharyngeal specimens were collected and transported at
2–8 C from the field site to the Infectious Disease Research Labo-
ratory (IDRL) in Karachi within 8 h of collection using established
World Health Organization’s (WHO) consensus methods [15].
2.3. Laboratory procedures
In the lab, samples were vortexed for 10–20 s to disperse the
organism and afterwards frozen at 80 C in an upright position
till time of further processing. For culture (batches of 20–40), sam-
ples were thawed, vortexed and 200 mL of a sample was added to
mixture of 1 mL rabbit serum, 5 mL Todd Hewitt broth with 0.5%
yeast extract and incubated for 6 h at 37 C. After this, one loop full
(10 ul) was inoculated onto bilayer sheep blood and colistin-
nalidixic-acid-agar and streaked for isolation of streptococci. After
18–24 h, plates were examined for the appearance of alpha-
hemolytic colonies and susceptibility to optochin and bile solubil-
ity. Serotypes were deduced using the published sequential multi-
plex PCR assay and further confirmation was done by monoplex
PCR [16,17]. Resolution of sero-group 6A/B/C/D was done as per
the methods described by Ping et al [18]. Identification of non-
typeable pneumococcal isolates (those with no positive results
for any of the 39 serogroups/ types) were confirmed with a lytA
Real time PCR as described by Carvalho MDG et al. [19]. Further
description of the laboratory methods is given in Figure s6-s8 in
the supplementary material.
2.4. Statistical analysis
Vaccine Type (VT) carriage was defined as isolation of any of the
10 serotypes included in PCV10 (serotypes 1, 4, 5, 6B, 7F, 9V, 14,
18C, 19F, 23F). Non-vaccine type (NVT) carriage was defined as
presence of all other pneumococci including the non-typeables.
PCV13 serotypes were defined as any of the PCV10 serotypes plus
serotypes 3, 6A and 19A. A study year ran from October to the
September of next year. We describe carriage rates by number of
the doses of the vaccine received and study year.
Measures of direct, indirect, total, and overall effects were cal-
culated using a modified Halloran Model described in Fig. 1. For
the estimate of carriage rate in a vaccine naïve population (the
unvaccinated compartment in the Halloran model), we used VT
carriage rate from a cross-sectional survey carried out in the same
population in January- February 2013 prior to introduction of PCV
10. Following definitions for the population-level impact of PCV10
VT carriage were used: Direct effect was calculated as 1– (VT car-
riage rate in children who received all three doses/VT carriage rate
in children who received zero dose); indirect effect was defined as
1- (VT carriage rate in children who received zero dose /26.7%
which was the pre-introduction VT carriage rate), total effect was
defined as 1-(VT carriage rate in children who received all three
doses/26.7%) and overall effect was defined as 1- (carriage rate in
the study population /26.7%). As a part of sensitivity analysis, we
excluded children who were too young to be fully vaccinated i.e.
<4 months of age and also compared VT carriage rate in those
who received 1 or more doses of PCV10 against those who did
not receive any dose. Logistic regression analysis was performed
to identify predictors of colonization with a PCV10 serotype. An
additional analysis was done to describe predictors of overall
pneumococcal carriage in these children. For the purpose of model
building all variables with a p-value less than 0.25 in the bivariate
analysis were used to build a multivariable model. A backward
selection procedure was used to derive a parsimonious model for
retaining only variables significant at p-value  0.05. All analysis
was performed using STATA version 15.0.
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Ethical approval was obtained from Aga Khan University’s Eth-
ical Review Committee (3181-Ped-ERC-14). A written informed
consent was obtained from all caretakers before commencing
enrollment.
2.5. Role of funding source
This study was funded by Bill & Melinda Gates Foundation
through grant # OPP1111303. Funder had no role in collection,
analysis or interpretation of the data.
3. Results
3.1. Characteristics of the study participants
We approached a total of 4181 households during the 4-year
study period from which 3140 children under the age of 2 years,
meeting our study criterion were enrolled after obtaining a written
informed consent from the primary care giver. The flow of the chil-
dren into the study is described in Fig. 2. Table 1 describes socio-
demographic and clinical history of the enrolled children. Mean
age was 10.5 months, half of the enrolled children were male,
the number of children too young to be fully vaccinated (4-
months) were 304 (9.7%), majority of the primary caretakers
2596 (82.7)% and half of the primary wage earners, 1671 (53.2%)
had no education at all; median household size was 8; one third
of children were exposed to environmental tobacco smoke (ETS);
natural gas was available in only 15% of the household and nearly
half of the children were exposed to indoor air pollution by cook-
ing. History of cough, runny nose and fever in past two weeks was
common. Six percent had fever at the time of enrollment, 7% had
tachypnea and 1.5% had chest wall indrawing. Vaccination cards
were available for 2388 (76.05%) children.
3.2. Carriage prevalence
All of the collected samples were analyzable. Pneumococcus
was detected in 2370 children (75.5%; 95% CI 74.0–77.0). Out of
these we were able to assign a serotype to 2155 (90.9%). Fig. 3
shows the VT and the ten most prevalent Non-Vaccine Type
(NVT) serotypes over the study period. Pneumococcal carriage
decreased from 80.8% in year 2014/15 to 72.8% in year 2017/18
Households approached  
(n=4181)
Locked Households (n=746) 
Death (n=186) 
Migraon (n=87) 
Refusal to consent (n=22) 
Total (n=1041) 
Households consented (n=3140) 
Children less than 2 years enrolled (n=3140) 
Total Nasopharyngeal Samples obtained 
(n=3140) 
Fig. 2. Flowchart describing study population.
Fig. 1. Schematic representation of direct, indirect, total and overall effect in two populations (modified from Halloran 2011) Direct effect was calculated as 1– (VT carriage
rate in children who received all three doses /VT carriage rate in children who received zero dose), indirect effect was defined as 1- (VT carriage rate in children who received
zero dose /26.7%), total effect was defined as 1-(VT carriage rate in children who received all three doses/26.7%) and overall effect was defined as 1- (carriage rate in the study
population / 26.7%).
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(p-value for trend 0.001 - Table 2 and Figure s1). VT carriage
decreased from 16.1% in year 2014/15 to 9.6% in 2017/18 (p-
value for trend <0.001). There was no change in prevalence of
the three serotypes included in PCV13 specific serotypes (3, 6A
and 19A) or NVT serotypes (p-value for trend = 0.202 and 0.999
respectively). Concurrently the proportion of children vaccinated
with all three doses of PCV10 (as per verbal report or card verifica-
tion) increased from 41.0% to 68.4%. (Table 3). In children who
received all 3 doses of PCV10, VT carriage decreased from 11.4%
(95% CI 8.1–15.4) in 2014 to 8.1% (95% CI 6.0–10.7) in 2018 (p-
value for trend 0.031) while in children who received one and
two doses VT carriage decreased from 24.7% (95% CI 16.0–35.3)
to 16.4% (95% CI 8.8–27.0) and from 20.0% (95% CI 12.7–29.2) to
12.3% (95% CI 6.7–20.1) respectively (p-value for trend 0.068 and
0.172) and in children who never received a PCV10 dose, VT
decreased from 17.4% (95% CI 13.1–22.5) in 2014 to 10.4%(95% CI
4.6–19.4) in 2018 (p-value for trend 0.003) (Table 4). Table s3
and s5 in the supplement give VT carriage by number of doses
and by age group.
3.3. Direct and indirect effects
Table 4 describes various measures of vaccine effectiveness. In
aggregate, the direct effect of the vaccine was calculated to be
32.8% (95% CI 14.7–47.0) and indirect effect was calculated to be
44.5% (95% CI 40.6–48.6). Total effect was shown to be 62.8%
(95% CI 60.5–65.0%) and overall effect to be 54.8% (95% CI 53.1–
56.5%). Table 4 also gives the variation in these effect estimates
over the years. Table s4 give the sensitivity analysis by including
children receiving 1 dose as vaccinated. This only slightly chan-
ged the estimates for direct and total effect. Table s5 and s6
describe the same analysis after dropping children who were too
young to have received all three doses of PCV10 (<4 months of
age). There were slight changes in the estimates which did not
have a significant impact on the overall results.
3.4. Risk factors for VT carriage
Table 5 shows association of different variables with PCV 10
type carriage. In the final adjusted model, history of a runny nose
in past two weeks (aOR 1.5, 95% CI 1.2–1.9) was positively associ-
Table 1
Socio-demographic and clinical characteristics of enrolled children, n = 3140.
Characteristics n (%)
Age
Mean (SD) in months 10.5 (6.0)
0–3 months 304 (9.7)
4–11 months 1604 (51.1)
12–23 months 1232 (39.2)
Males 1580 (50.3)
Primary caretaker education
No education 2596 (82.7)
1–5 years 351 (11.2)
6–16 years 193 (6.1)
Primary wage earner education
No education 1671 (53.2)
1–5 years 761 (24.2)
6–16 years 708 (22.5)
People in the household, median (IQR) 8 (6–11)
Number of rooms in house, median (IQR) 1 (1–2)
Crowding index *, median (IQR) 5.5 (4–7)
Hospital Admissions in last year
None 3046 (97.0)
One 83 (2.6)
Two or more 11 (0.4)
Outpatient visits in last month
None 1611 (51.3)
One 797 (25.4)
Two or more 732 (23.3)
Smoker in household 1116 (35.5)
Fuel used for cooking
Wood/paper/straw/crop/animal dung 2640 (84.1)
Natural Gas 485 (15.4)
Other 15 (0.5)
Child exposed to smoke during cooking 1689 (53.8)
Symptoms during last two weeks**
Runny nose 1 584 (51.6)
Cough 1 220 (39.8)
Fever 1 463 (47.7)
Fast breathing 79 (2.6)
Difficulty in breathing 612 (19.9)
Lower chest indrawing 74 (2.4)
Signs**
Hypothermia <35 C 11 (0.4)
Hyperthermia >37.5 187 (6.1)
Tachypnea*** 210 (6.9)
Lower chest indrawing 47 (1.5)
IQR = Interquartile Range, * defined as no. of persons/room, **data available for
3068 children, ***using WHO age-specific cutoffs.
Fig. 3. Ten most prevalent Vaccine-Type and NVT serotype distribution over the years (2014–2018).
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ated with VT carriage. On the other hand, primary wage earner
having 1–5 years of education (aOR 0.7, 95% CI 0.6–1.0), history
of difficulty in breathing in past two weeks (aOR 0.7, 95%CI 0.5–
1.0), exposure to environmental tobacco smoke (aOR 0.8, 95% CI
0.6–1.0), having received 3 doses of PCV10 (aOR 0.7, 95%CI 0.5–
1.0) and being enrolled in 3rd (aOR 0.6, 95%CI 0.4–0.8) and 4th year
(aOR 0.6, 95%CI 0.5–0.9) of the study were negatively associated
with VT carriage.
4. Discussion
Vaccine Type carriage declined significantly in our study popu-
lation with modest increases in vaccine coverage. When compared
to the pre-introduction VT carriage rate of 26.7% in the same pop-
ulation, a greater than 50% decline was observed in the unvacci-
nated group at third year of the study with a vaccine coverage of
66.0%. This critical cutoff is described in literature as the vaccine
threshold required to achieve herd effect. Loughlin et al have
reported this threshold to be around 75% in Massachusetts, USA
[20]. At the end of 4 years, VT carriage in the unvaccinated declined
further to 10.3% - a total of 61.4% decline at 68.4% vaccine coverage.
For all children under 2 years of age, VT carriage was 9.6% at the
end of 4 years - a decline of 64% from pre introduction levels. In Sao
Paulo, Brazil two years after the introduction of PCV 10, VT carriage
declined by more than 90.9% % from 19.8% to 1.8% in children aged
12–23 months. An important difference here is a high vaccine cov-
Table 2











No. positive for pneumococcus 623 574 583 590 2370










No. positive for PCV10 serotypes 124 102 75 78 379










No. positive for 3 PCV13 serotypes 82 80 97 98 357










No. positive for NVT serotypes 499 473 508 510 1990










*p value for trend is 0.001 €p value for trend is <0.001 1 p value for trend is 0.202 pp value for trend is 0.999.
Table 3
Number of vaccine doses received among study participants by year.
No. of PCV doses 2014–2015 (n = 771) 2015–2016 (n = 780) 2016–2017 (n = 779) 2017–2018 (n = 810) 2014–2018 (n = 3140)






































p-value for trend 0.001.
Table 4
Direct, Indirect, Total and Overall effect of PCV10 on VT carriage (0 dose vs 3 doses).
Year 2014–2015 2015–2016 2016–2017 2017–2018 2014–2018
















































































VT carriage prior to PCV10 introduction was taken as 26.7% *p-value for trend 0.031, a p-value for trend 0.172, b p-value for trend 0.068, 1p-value for trend 0.003.
Direct effect was calculated as 1– (VT carriage rate in children who received all three doses /VT carriage rate in children who received zero dose), indirect effect was
defined as 1- (VT carriage rate in children who received zero dose /26.7%), total effect was defined as 1-(VT carriage rate in children who received all three doses/
26.7%) and overall effect was defined as 1- (carriage rate in the study population / 26.7%).
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erage of 93% and a 3 + 1 schedule [21]. In Mongolia which imple-
mented a 2 + 1 regimen for PCV13, a 53.3% % decline in VT carriage
from 42.2% to 19.7% was observed one year after introduction in
children 12–23 months of age at vaccine coverage of 18% for three
doses and 95% for 2 doses. Thus a 2-dose regimen in Mongolia
appeared to perform well [22]. In The Gambia VT carriage declined
by 65.7%, from 33.3% to 11.4% five years post introduction of PCV13
in the background of more than 95% vaccine coverage and a 3 + 0
schedule [23]. In Lao PDR, which also used PCV13 as a 3 + 0 regi-
men, a 39.8% decline from 32.9% to 19.8% in VT carriage was
observed with greater than 90% vaccine coverage [24]. In Kenya,
where they used a 3 + 0 schedule for PCV10, a 74% decline from
33.8% to 8.8% over 7 years with greater than 80% vaccine cover-
age[25]. Three years after introduction of PCV 10 with a 3 + 0
schedule in Mozambique, vaccine-type carriage declined by almost
43% in both HIV infected and healthy children aged less than
5 years in whom just 34.1% had received three doses of PCV 10
[26]. PCV 10 serotypes declined by 67.2% in Fiji in children aged
1–2 years three years post PCV 10 introduction in a 3 + 0 schedule
and vaccine coverage was 100% by the final year of study [27]. As
Table 5
Predictors of PCV10 serotype carriage in children <2 years of age, n = 3140.
PCV 10 negative PCV 10 positive Adjusted Model
n(%) n(%) OR (95% CI) aOR (95% CI)
N 2761 379
Age group (months)
0–11 months 1679 88 229 12 Ref
12–23 months 1082 87.8 150 12.2 1.0 (0.8–1.3)
Gender
Male 1394 50.5 186 49.1 Ref
Female 1367 49.5 193 50.9 1.1 (0.9–1.3)
Primary care taker’s education
No education 2281 82.6 315 83.1 Ref
1–5 years 307 11.1 44 11.6 1 (0.7–1.5)
6–16 years 173 6.3 20 5.3 0.8 (0.5–1.3)
Primary wage earner’s education
No education 1454 52.7 217 57.3 Ref Ref
1–5 years 686 24.9 75 19.8 0.7 (0.6–1) 0.7 (0.6 – 1.0)
6–16 years 621 22.5 87 23.0 0.9 (0.7–1.2) 1 (0.8–1.3)
People in household, median (IQR) 8 6–11 8 6–11 1.0 (1.0–1.0)
No. of rooms in house 1 1–2 1 1–2 1.0 (0.9–1.1)
Crowding Index 6 4–7 6 4–7.5 1.0 (1.0–1.1)
Symptoms (in last 2 weeks) *
Runny nose 1364 50.6 220 59.3 1.4 (1.1–1.8) 1.5 (1.2–1.9)
Cough 1046 38.8 174 46.9 1.4 (1.1–1.7)
Fever 1284 47.6 179 48.3 1 (0.8–1.3)
Fast breathing 65 2.4 14 3.8 1.6 (0.9–2.9)
Difficulty in breathing 548 20.3 64 17.3 0.8 (0.6–1.1) 0.7 (0.5 – 1.0)
Lower Chest indrawing 61 2.3 13 3.5 1.6 (0.9–2.9)
Temperature
Hypothermia 9 0.3 2 0.5 Ref
Normal temperature 2523 93.6 347 93.5 0.6 (0.1–2.9)
Hyperthermia 165 6.1 22 5.9 0.6 (0.1–3)
Tachypnea 182 6.8 31 8.4 1.3 (0.8–1.9)
Lower chest indrawing 46 1.7 1 0.3 0.2 (0.0–1.1)
Hospitalization in past 12 months
No 2678 97.0 368 97.1 Ref
Yes 83 3.0 11 2.9 1 (0.5–1.8)
Outpatient visits in past one month
None 1424 51.6 187 49.3 Ref
One 703 25.5 94 24.8 1 (0.8–1.3)
Two or more 634 23.0 98 25.9 1.2 (0.9–1.5)
Exposure to ETS 993 36.0 123 32.5 0.9 (0.7–1.1) 0.8 (0.6–1)
Cooking Fuel
Natural gas 431 15.6 54 14.3 Ref
Wood/paper/straw/crop residue/animal dung 2317 83.9 323 85.2 1.1 (0.8–1.5)
Other 13 0.5 2 0.5 1.2 (0.3–5.6)
Child exposed to smoke (<2 m) 1493 54.1 196 51.7 0.9 (0.7–1.1)
No of PCV 10 doses
Zero 501 18.2 87 23.0 Ref Ref
One 289 10.5 61 16.1 1.2 (0.8–1.7) 1.3 (0.9–1.9)
Two 339 12.3 50 13.2 0.8 (0.6–1.2) 1 (0.7–1.4)
Three 1630 59.1 180 47.6 0.6 (0.5–0.8) 0.7 (0.5–1)
Year of enrollment
2014/15 647 23.4 124 32.7 Ref Ref
2015/16 678 24.6 102 26.9 0.8 (0.6–1) 0.8 (0.6–1)
2016/17 704 25.5 75 19.8 0.6 (0.4–0.8) 0.6 (0.4–0.8)
2017/18 732 26.5 78 20.6 0.6 (0.4–0.8) 0.6 (0.5–0.9)
*this was not included in multivariable analysis, instead no of PCV doses was used. ETS-Environmental Tobacco Smoke.
Tachypnea is defined as: Children younger than 2 months - Greater than or equal to 60 breaths/min, children aged 2–11 months - Greater than or equal to 50 breaths/min,
children aged 12–59 month - Greater than or equal to 40 breaths/min
Hypothermia is defined as underarm temperature below 35.0 C (95.0 F), Hyperthermia is defined as underarm temperature 38.0 C (100.4 F).
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seen above the decline in VT carriage was higher in most of these
countries post introduction, that can be most likely attributed to
higher vaccine coverage.
To describe the estimates of direct and indirect effect, we took a
novel approach using a modified Halloran model which used the
pre-introduction carriage levels in the absence of a concurrent
unvaccinated population. For the direct effect we compared the
vaccinated children (3 doses) against the unvaccinated children
(0 dose) in the study population. We looked at indirect effect in
two ways- first in the form of decline in the unvaccinated group
over the course of four years. Secondly, we calculated a more for-
mal measure of indirect effect by comparing VT carriage in the
unvaccinated group (0 dose) with the pre-introduction VT carriage
[14]. This is a slightly different approach from other studies
reported in literature where the comparison is made usually with
the adult population, older children or the group too young to be
vaccinated or a concurrent population where the vaccine has not
been introduced. These groups would contain vaccinated children
overtime and thus underestimate the indirect effect seen in the
population. The benefit of including a pre-introduction comparison
group of same age is that they would have accrued similar expo-
sure time. Moreover, both the pre and post introduction study
samples shared similar baseline characteristics. The vaccine
demonstrated significant direct effect which however declined
over time due to increasing indirect effect. This is a bit counterin-
tuitive but is in fact a reflection of the herd effect in the unvacci-
nated group and is in accordance with the Halloran model.
Our estimate of indirect effect was also comparable to other
published studies. In Mozambique, three years after the introduc-
tion, VT carriage declined by 30% from 39.1% to 27.3% with a vac-
cine coverage of 34.1%, among HIV-infected unvaccinated
children aged 24–59 months [26]. In The Gambia, mothers of fully
vaccinated children who received all the PCV doses showed a VT
carriage decline of 33.3% from 8.4% to 5.6% [23]. In Kenyan children
aged 5–14 years, VT carriage declined by 61.4% from 15.3% to 5.9%
and a decline of 75.4% (from 5.7% to 1.4%) was noted in the popu-
lation aged 15 years and above [25]. In Malawi, VT carriage
declined by 63.6% from 21.2% to 7.7% in 5–15 years old children
and from 6.6% to 2.4% in mothers of vaccinated children [28]. Sim-
ilar decline was observed in Fiji in children aged 2–6 years where
VT carriage declined by 58% from 21.7% to 9.1% and in their care-
givers from 2.4% to 0.8% - a 66.6% decline [27]. In Iceland, children
aged 3.5–6.3 years showed a 48.7% decline in VT carriage and in
Finland a decline of 29% was reported in older siblings of children
who were vaccinated with PCV10 [29 30]. PCV13 carriage in Nor-
way declined in older than 24-month age population from 14.6%
to 4.9% - a decline of 66.4% [31]. A study in Boston reported a sus-
tained 50% reduction in the PCV13 serotype carriage in unvacci-
nated children at a vaccine coverage of 80% [20]. In Mongolia,
where they looked at the indirect effect in children too young to
be vaccinated, a 51% decline in VT carriage from 12.9 to 6.3% was
observed in children aged 5–8 weeks [22]. In Fiji, the VT carriage
declined by 39% from 9.6% to 5.8% in the 5–8 weeks age group [27].
In this study sample, partially vaccinated children (those receiv-
ing either one or two doses only) had similar VT carriage rates as
the unvaccinated group. This is important in context of reduce dose
regimens that have been advocated in many developed countries
like UK but might prove to be inefficient in our setting [32].
There was no difference in VT carriage rate when we divided the
age into three categories, however looking at the overall pneumo-
coccal carriage, when compared to 4–11 months, the children too
young to be vaccinated were less likely to be positive (OR 0.6,
95% CI 0.5–0.8) while children 12–23 months were more likely to
be positive (OR 1.3, 95% CI 1.1–1.6). This reflects increased acquisi-
tion of S. pneumoniae through early infancy and childhood.
The overall carriage in our study was very high and remained
high 4 years after introduction which is comparable to what has
been reported previously in several other studies from low and
middle-income countries. A study in Kenya reported an overall car-
riage rate of 76% in under 5 children, five years after introduction
of PCV10 [25], overall carriage was 85% in The Gambian children
aged 6–12 months 5 years after introduction of PCV13 [23,33]. In
Mozambique two years after introduction of PCV10, the overall
carriage was 84.8% in children under 5 years of age [26]. This over-
all carriage is however high in comparison to what has been
reported in many of the developed countries. The overall carriage
rate in children in Boston two years after PCV 13 introduction
was 24%. In the UK, six years after PCV 13 introduction, overall car-
riage rates in children less than five years were 51.9% whereas in
Sweden overall carriage rates were 30% post-PCV introduction
[20,34,35]. This difference is observed despite high vaccine cover-
age rates in some of the African populations. Reasons for this are
not clearly understood but it might be related to differences in
microbial serotype diversity in the regions as well as the pre intro-
duction carriage rates. We saw a modest decline in the overall car-
riage which was attributable to the decline in vaccine type
carriage. Many of the other studies reported either non-
significant declines or even increases in overall carriage rates due
to increase in serotypes not covered by the vaccine. So as expected,
even in our study the decrease in VT carriage was partially offset by
increases in NVT and specifically with the three PCV13 serotypes
not included in PCV10. Results from serotype distribution show a
large proportion contributed by the three PCV13 specific serotypes
and nearly 70 percent non-vaccine type serotypes. This points
towards a need for development of a vaccine with pan-serotype
coverage. The overall carriage decreased over time with no concur-
rent rise in NVT carriage.
Results from regression modelling show a vaccine effectiveness
of 40% for VT carriage, with increasing efficacy with increasing
numbers of PCV10 doses. Of the predictors of VT carriage, nothing
was associated with carriage except runny nose affirming previous
work. Loughlin et al reported having respiratory symptoms at time
of enrollment, especially having a runny nose or earache as strong
predictors of colonization [20]. Mackenzie et al. showed over 3-fold
higher rates of VT carriage in children with runny nose in the pre-
vious week [36] and Adetifa et al. showed nearly 50% increased
rates of VT carriage in children with recent runny nose [37]. Finn
et al reported associations between both rhinitis symptoms and
respiratory viral infections and pneumococcal carriage in the
nasopharynx. Pneumococcus became more easily detectable in
the presence of rhinovirus infection [38]. In our study we found a
negative association between ETS and VT carriage which is in con-
tradiction with other reports [39]. Greenberg et al. showed high
rates of VT carriage in children exposed to tobacco smoke [40].
We report an inverse relationship which could be spurious in nat-
ure or inability of the tool to capture the symptom history
accurately.
In analysis for overall carriage, age group 12–23 months and
runny nose was positively associated whereas an age group of 0–
3 months, higher education status of primary caretaker, difficulty
breathing, being enrolled in the third and final years of the study
showed a negative association. These results are described in
supplement.
This is the first study to come out from Pakistan reporting
impact of introduction of PCV10 on nasopharyngeal carriage in
children. Riaz et al report impact of PCV10 on Invasive Pneumococ-
cal Disease across a network of hospitals in Karachi. In the case
control analysis vaccine effectiveness for three doses was calcu-
lated to be 81.9% but with large non-significant confidence inter-
vals because of small sample size [41]. We used standardized
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WHO and CDC protocols for collection and laboratory analysis.
Ours was a large study spread over a period of 4 years which
allowed us to look at temporal trends and draw inferences. One
limitation of our study was that we did not check for multiple ser-
otypes and carriage density and thus could not look at co-carriage.
The serotyping method used allowed for testing of only 39 of the
nearly 100 known pneumococcal serotypes. Our study was
performed in a small rural district of Matiari which may not be
representative of the entire population of Pakistan. Since our study
was performed in healthy children, we may have missed to detect
highly invasive serotypes like 1, 12F and 5 that commonly cause
outbreaks of disease but are rarely carried and may only be tran-
siently detectable in carriage during outbreaks. In cases where
vaccination card was not available, vaccine status ascertainment
was made solely on the basis of recall and common practices
which may have resulted in misclassification though we tried to
address this by performing various sensitivity analysis. In our
study we report a high prevalence of respiratory symptoms at
the time of enrolment which could be due to over reporting by
the caregivers.
We acknowledge that vaccine coverage might have declined
after the study was completed and there is a need for continuous
surveillance to detect change in carriage distribution.
5. Conclusion
Our study provides evidence that a 3 + 0 schedule works well in
the setting of a lowmiddle income country in providing both direct
and indirect protection to children. To maximally capitalize on
these benefits, a high and sustained vaccine coverage with contin-
uous monitoring for disease and carriage prevalence for emerging
serotypes is required.
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